Search

Your search keyword '"Furtado, Remo"' showing total 216 results

Search Constraints

Start Over You searched for: Author "Furtado, Remo" Remove constraint Author: "Furtado, Remo" Search Limiters Full Text Remove constraint Search Limiters: Full Text
216 results on '"Furtado, Remo"'

Search Results

2. Abstract 10481: The Effect of Current Smoking on Platelet Reactivity Measures by Point-of-Care Methods in Patients Treated With and Without Clopidogrel

4. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization

9. Long-term outcomes among stable post-acute myocardial infarction patients living in rural versus urban areas: insights from the prospective, observational TIGRIS registry

12. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.

13. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

14. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

15. Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial

16. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

17. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

18. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

19. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction

20. Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction

21. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B

22. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial

23. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

24. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

25. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.

26. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention

27. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials

28. Abstract 12524: Very Long-term Mortality After St Elevation Myocardial Infarction (stemi) Complicated By Cardiogenic Shock

29. Abstract 10724: Long-Term Mortality After Acute Coronary Syndromes Among Patients with Normal, Mid-Range or Low Ejection Fraction

30. Abstract 13729: Monotherapy With a P2Y12 Inhibitor versus Aspirin for Secondary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) Events: A Meta-Analysis of Randomized Trials

31. Abstract 13782: Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel

32. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.

33. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021

34. SAFETY AND EFFICACY OF DPP4 INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: A BIOMARKER DRIVEN DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL

35. HIGH-DENSITY LIPOPROTEIN FUNCTION IN PATIENTS WITH TYPE 2 DIABETES: DIFFERENCES BETWEEN THE ACUTE AND CHRONIC PHASES OF CORONARY ARTERY DISEASE

37. INFLUENCE OF HEALTH INSURANCE ON LONG-TERM ADHERENCE TO STATINS AND BETA-BLOCKERS AFTER ACUTE CORONARY SYNDROMES

38. BIOMARKER PREDICTION OF MAJOR CORONARY EVENTS AND COMPLEX REVASCULARIZATION PROCEDURES IN PATIENTS WITH STABLE ATHEROSCLEROSIS

39. Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction

40. Associação entre Terapia com Estatinas e Menor Incidência de Hiperglicemia em Pacientes Internados com Síndromes Coronarianas Agudas

41. Factors associated with actively working in the very long-term following acute coronary syndrome

42. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

43. COMPARISON BETWEEN TWO DIFFERENT LOCAL HEMOSTASIS TECHNIQUES FOR DENTAL EXTRACTIONS IN PATIENTS ON DUAL ANTIPLATELET THERAPY: A WITHIN-PERSON, SINGLE-BLIND, RANDOMIZED TRIAL

44. ELECTRICAL STORM AND CARDIOGENIC SHOCK AFTER ACUTE CORONARY SYNDROME REVERTED WITH ECMO CASE REPORT

45. IMPACT OF HIGH LIPOPROTEIN(A) LEVELS ON PLATELET AGGREGABILITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE

46. EFFECT OF EXERCISE TRAINING ON PLATELET AGGREGATION AND ON P2Y12 INHIBITOR RESISTANCE AFTER MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

49. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54

50. DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL

Catalog

Books, media, physical & digital resources